Join the discussion.


Back to full list

Recent Webinars

Hereditary gynecologic cancers: An overview and case studies

Tali Ekstein, MS, LCGC, Invitae
April 01, 2015
Series: ZinniaEntrySeries object
View Recording

As many as 5 to 15% of gynecological cancers are inherited. In this webinar, Invitae’s genetic counselor, Tali Ekstein, will review Invitae’s Hereditary Gynecologic Cancers Panel. We will discuss when this panel may be considered, review the key genes, and cover case studies related to ovarian and endometrial cancers. We will also review how the information obtained from genetic testing may benefit your patient and their family members.


High-risk breast cancer genes: Current approaches in community oncology

Raluca Kurz, MS, LCGC, Invitae
January 28, 2015
Series: ZinniaEntrySeries object
View Recording

Hereditary cancer syndrome testing is becoming increasingly prevalent, yet adoption by community oncology practices has been minimal. Raluca Kurz, a genetic counselor at Invitae, will discuss current drawbacks to incorporating genetic testing into a community oncology practice and how Invitae is helping to overcome these barriers.

Examples include report interpretation, turnaround time, and genetic counseling. We’ll discuss BRCA and the high-risk breast cancer genes as well as management guidelines. The webinar will close with a few case studies of reviewing a family history and then choosing the correct test for your patient.

Finding the needle in the haystack: The use of multi-gene panels in oncology

Heather Hampel, MS, CGC and Tuya Pal, MD
May 12, 2014
Series: ZinniaEntrySeries object
View Recording

The use of multi-gene panels in hereditary cancer clinics is increasing. Heather Hampel, MS, CGC and Tuya Pal, MD will present cases from their clinical experience that have utilized panel testing. The speakers will highlight the potential benefits of panels as well as difficulties including managing patient expectations, dealing with positive results in moderate penetrance genes and multiple VUSes per patient.

Can multi-gene panels allow us to provide additional genetic guidance and screening to improve patient care?

Allison Kurian, MD, MSc
May 08, 2014
Series: ZinniaEntrySeries object
View Recording

New research findings from Stanford published in JCO on multi-gene panels for hereditary cancers: what have we learned about improving patient care?

According to a new publication from Stanford in the Journal of Clinical Oncology, as many as 10 percent of women with a personal or family history of breast or ovarian cancer have at least one genetic mutation that, if known, would prompt their doctors to recommend changes in their care, according to a new study by researchers at the Stanford University School of Medicine.

The women in the study did not have mutations in BRCA1 or BRCA2 (mutations in these genes are strongly associated with hereditary breast and ovarian cancer), but they did have mutations in other cancer-associated genes.

The study was conducted using what’s known as a multiple-gene panel to quickly and cheaply sequence just a few possible genetic culprits selected by researchers based on what is known about a disease. Although such panels are becoming widely clinically available, it’s not been clear whether their use can help patients or affect medical recommendations.

This seminar aims to answer those questions, both from the research study, featuring lead author Dr. Allison Kurian.